• 1. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 5. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines

Recent Advances in the Study of (3R,4R)-4-methoxypyrrolidin-3-ol (CAS: 473298-17-8) in Chemical Biology and Pharmaceutical Research

The compound (3R,4R)-4-methoxypyrrolidin-3-ol (CAS: 473298-17-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This chiral pyrrolidine derivative serves as a key intermediate in the synthesis of various biologically active molecules, particularly those targeting central nervous system (CNS) disorders and infectious diseases. Recent studies have highlighted its potential as a building block for novel therapeutic agents, with particular emphasis on its role in modulating neurotransmitter systems and enzyme inhibition.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of (3R,4R)-4-methoxypyrrolidin-3-ol derivatives as potent inhibitors of monoamine oxidase B (MAO-B), an enzyme implicated in neurodegenerative diseases such as Parkinson's. The research team utilized molecular docking simulations to optimize the compound's stereochemistry, resulting in derivatives with improved blood-brain barrier permeability and selectivity profiles. These findings suggest promising avenues for developing new anti-Parkinsonian drugs based on this scaffold.

In antimicrobial research, a recent publication in Bioorganic & Medicinal Chemistry Letters (2024) reported the synthesis of novel (3R,4R)-4-methoxypyrrolidin-3-ol-containing analogs with remarkable activity against drug-resistant bacterial strains. The study revealed that the compound's methoxy group plays a crucial role in enhancing membrane penetration, while the hydroxyl group contributes to target binding specificity. These structural features make it particularly valuable for designing next-generation antibiotics addressing the global antimicrobial resistance crisis.

From a synthetic chemistry perspective, advancements in the asymmetric synthesis of (3R,4R)-4-methoxypyrrolidin-3-ol have been achieved through innovative catalytic methods. A 2023 Nature Catalysis paper described a biocatalytic approach using engineered transaminases that achieved >99% enantiomeric excess with significantly improved yield compared to traditional chemical routes. This breakthrough has important implications for scaling up production while maintaining the high stereochemical purity required for pharmaceutical applications.

The pharmacokinetic properties of (3R,4R)-4-methoxypyrrolidin-3-ol derivatives have also been extensively investigated in recent preclinical studies. Research published in Drug Metabolism and Disposition (2024) demonstrated favorable metabolic stability and low cytochrome P450 inhibition potential for several lead compounds derived from this scaffold. These characteristics, combined with the molecule's relatively low toxicity profile as evidenced by in vitro and in vivo safety assessments, position it as an attractive candidate for further drug development.

Looking forward, the unique structural features of (3R,4R)-4-methoxypyrrolidin-3-ol continue to inspire novel applications in medicinal chemistry. Current research directions include its incorporation into PROTAC (proteolysis targeting chimera) designs for targeted protein degradation and as a component of covalent inhibitors for challenging therapeutic targets. The compound's versatility and demonstrated biological activities ensure it will remain an important focus of chemical biology research in the coming years.

• 1212158-80-9(trans-4-Isopropoxypyrrolidin-3-ol)
• 596793-29-2((3S,4S)-3,4-dimethoxypyrrolidine)
• 473298-16-7((3R,4R)-4-methoxypyrrolidin-3-ol hydrochloride)
• 473298-21-4((3S,4S)-4-methoxypyrrolidin-3-ol)
• 412279-17-5(trans-4-Methoxy-3-pyrrolidinol hydrochloride)
• 55619-48-2(3,4-dimethoxypyrrolidine)
• 473298-25-8((3R,4S)-4-methoxypyrrolidin-3-ol)
• 473298-19-0(trans-4-Methoxypyrrolidin-3-ol)
• 473298-29-2((3S,4R)-4-Methoxypyrrolidin-3-ol hydrochloride)
• 473298-23-6((3S,4S)-4-methoxypyrrolidin-3-ol hydrochloride)